<figure><img src="image_1.png" /></figure>

HAL
open science

# Using Digital Tools to Advance Alzheimer's Drug Trials During a Pandemic: The EU/US CTAD Task Force

J. Kaye, P. Aisen, R. Amariglio, R. Au, C. Ballard, M. Carrillo, H. Fillit, T.

Iwatsubo, G. Jimenez-Maggiora, S. Lovestone, et al.

► To cite this version:

J. Kaye, P. Aisen, R. Amariglio, R. Au, C. Ballard, et al. Using Digital Tools to Advance Alzheimer's Drug Trials During a Pandemic: The EU/US CTAD Task Force. The Journal of prevention of Alzheimer's disease, 2021, 8 (4), pp.513-519. 10.14283/jpad.2021.36. hal-04500525

HAL Id: hal-04500525

https://ut3-toulouseinp.hal.science/hal-04500525v1

Submitted on 9 Oct 2025

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_2.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
# Using Digital Tools to Advance Alzheimer's Drug Trials During a Pandemic: The EU/US CTAD Task Force

J. Kaye¹, P. Aisen², R. Amariglio³, R. Au⁴, C. Ballard⁵, M. Carrillo⁶, H. Fillit⁷, T. Iwatsubo⁸, G. Jimenez-Maggiora², S. Lovestone⁹, F. Natanegara¹⁰, K. Papp³, M.E. Soto¹¹, M. Weiner¹², B. Vellas¹³, and the EU/US CTAD Task Force

*EU/US/CTAD TASK FORCE: Sandrine Andrieu (Toulouse); Matthew Barton (Raleigh); Randall Bateman (Saint Louis); Monika Baudler (Basel); Joanne Bell (Willington); Kevin Biglan (Indianapolis); Adam Boxer (San Francisco); Sasha Bozeat (Basel); Claudine Brisard (Issy les Moulineaux); Miroslaw Brys (Indianapolis); Marc Cantillon (Gilbert); Bill Chan (Beijing); Ivan Cheung (Woodcliff Lake); Min Cho (Woodcliff Lake); Julia Coelho (San Francisco); Shobha Dhadda (Woodcliff Lake); Daniel Di Giusto (Basel); Michael Donohue (San Diego); Rachelle Doody (Basel); John Dwyer (Washington); Michael Egan (North Wales); Rianne Esquivel (Malvern); Wendy Galpern (New Jersey); Harald Hampel (Woodcliff Lake); Jason Hassenstab (St Louis); David Henley (New Jersey); Joseph Herring (North Wales); Carole Ho (South San Francisco); Michael Irizarry (Woodcliff Lake); Keith Johnson (Boston); Geoffrey Kerchner (South San Francisco); Gene Kinney (South San Francisco); Shailaja Korukonda (Woodcliff Lake); Lynn Kramer (Woodcliff Lake); Jaren Landen (Cambridge); Ishani Landri (Woodcliff Lake); Lars Lannfelt (Uppsala); Valérie Legrand (Nanterre); Manoj Malhotra (Woodcliff Lake); Eric McDade (St Louis); Francisco Nogueira (South San Francisco); Gerald Novak (New Jersey); Gunilla Osswald (Stockholm); Susanne Ostrowitzki (South San Francisco); Amanda Paley (New York); Martin Rabe (Woodcliff Lake); Rema Raman (San Diego); Elena Ratti (Cambridge); Laurie Ryan (Bethesda); Stephen Salloway (Providence); Peter Schüler (Langen); Hiroshi Sekiya (Malvern); Jiong Shi (Las Vegas); Melanie Shulman (Cambridge); Eric Siemens (Zionsville); John Sims (Indianapolis); Kaycee Sink (South San Francisco); Reisa Sperling (Boston); Joyce Suhy (Newark); Jina Swartz (London); Pierre Tariot (Phoenix); Edmond Teng (South San Francisco); Jacques Touchon (Montpellier); Martin Traber (Basel); Andrea Vergallo (Woodcliff Lake); Judy Walker (Singapore); Jon Walsh (San Francisco); Alette Wessels (Indianapolis); Haichen Yang (North Wales); Wagner Zago (San Francisco); Kenton Zavitz (Cambridge).

1. Layton Aging and Alzheimer's Disease Center, School of Medicine, Oregon Health and Science University, Portland, OR, USA; 2. Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA, USA; 3. Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; 4. Boston University, Boston, MA, USA; 5. University of Exeter, Exeter, UK; 6. Alzheimer's Association, Chicago IL, USA; 7. Alzheimer Drug Discovery Foundation, New York, NY, USA; 8. University of Tokyo, Tokyo, Japan; 9. Janssen Pharmaceutical Company, High Wycombe, UK; 10. Eli Lilly and Company, Indianapolis IN, USA; 11. Toulouse University Hospital, Toulouse, France; 12. University of California, San Francisco CA, USA; 13. Gerontopole, INSERM U1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France

*Corresponding Author:* Jeffrey Kaye, Layton Aging and Alzheimer's Disease Center, School of Medicine, Oregon Health and Science University, Portland, OR, USA, kaye@ohsu.edu

## Abstract

The 2020 COVID-19 pandemic has disrupted Alzheimer's disease (AD) clinical studies worldwide. Digital technologies may help minimize disruptions by enabling remote assessment of subtle cognitive and functional changes over the course of the disease. The EU/US Clinical Trials in Alzheimer's Disease (CTAD) Task Force met virtually in November 2020 to explore the opportunities and challenges associated with the use of digital technologies in AD clinical research. While recognizing the potential of digital tools to accelerate clinical trials, improve the engagement of diverse populations, capture clinically meaningful data, and lower costs, questions remain regarding the stability, validity, generalizability, and reproducibility of digital data. Substantial concerns also exist regarding regulatory acceptance and privacy. Nonetheless, the Task Force supported further exploration of digital technologies through collaboration and data sharing, noting the need for standardization of digital readouts. They also concluded that while it may be premature to employ remote assessments for trials of novel experimental medications, remote studies of non-invasive, multi-domain approaches may be feasible at this time.

**Key words:** Alzheimer's disease, clinical outcomes, digital tools, remote assessments.

## Introduction

The 2020 COVID-19 pandemic disrupted clinical trials worldwide as health care facilities became overwhelmed and lock-down conditions shuttered clinical trial sites, forcing both study staff and trial participants to stay home (1–3). Nearly every ongoing clinical study has felt the impact, although the degree of impact varies. Alzheimer's disease (AD) studies have been acutely affected for multiple reasons, including: 1) the increased vulnerability to COVID-19 of people with or at risk of AD due to their advanced age and high prevalence of comorbid conditions; 2) the effects of even mild cognitive decline on the ability of participants to comply with the operational changes in how trials are conducted (e.g., social distancing from study staff and study partners, changes in study protocols); and 3) effects on clinical endpoints due to isolation, confusion, and behavioral and psychological symptoms of dementia (BPSD) such as agitation, apathy, and depression (1, 4). Other disruptions common to all clinical trials including those for AD interventions include: 1) reduced clinical capacity; 2) increased costs due to the need for increased personal protective equipment (PPE) and infrastructure for altered intervention delivery; 3) delays in ethics approvals as institutional review boards (IRBs) are swamped with COVID-19 related protocols; 4) reluctance of patients and participants to be in contact with clinics and health
providers; and 5) suspension of patient screening and
recruitment.

Study sponsors have responded to these challenges
in different ways; for example, by mailing drugs to
trial participants to ensure participants have access
to interventions; limiting clinic visits through the
establishment of alternative trial sites; allowing a brief
hiatus from dosing; and implementing home infusions.
Funders have also responded with innovations. In an
analysis of their funding portfolio during the latter half
of 2020, the Alzheimer's Drug Discovery Foundation
(ADDF) found that about 70% of grantees expected
their studies to be delayed, and some requested no-cost
extensions. Delays may harm not only budgets but
data analyses as well, since data interpretation can be
muddled due to long-term disruptions, missing data, and
protocol deviations; with clinical studies more affected
than preclinical studies. Observational studies have
also been affected. For example, Swedish BioFINDER2
halted enrollment, and the Rush University aging cohort
studies stopped performing autopsies due to lack of
PPE. In response to these challenges, the Alzheimer's
Association introduced a Rapid Program in Dementia
(RAPID) funding program to provide bridge funding for
Association-funded research during the pandemic.

In March 2020, the U.S. Food and Drug Administration (FDA) issued guidelines on the conduct of clinical trials during the pandemic and updated this guidance in December 2020 (5). The guidance aims to protect the safety of trial participants while ensuring good clinical practice and trial integrity. It also recognized the likely use of remote assessments and new technologies for data acquisition.

In recent years, digital technologies that enable remote
assessment and gather real-world granular data on
a variety of cognitive and functional outcomes have
received increased attention and interest in the AD drug
development community (6). Recognizing the urgency
of developing these technologies due to the pandemic,
the EU/US CTAD Task Force met in November 2020
to address the topic, bringing together an international
group of clinical investigators from academia and
industry along with funders. They explored emerging
digital technologies that are being used in clinical
research as well as the challenges that have yet to be
addressed to realize the potential of these technologies.
First and foremost, they recognized that global challenges
such as the COVID-19 pandemic require global solutions.

Opportunities and challenges to make trials
more robust using digital technologies

Even if there were no pandemic, clinical trials as
currently conducted are too slow and costly to adequately
respond to a disease such as Alzheimer's, which currently
affects around 50 million people worldwide and for
which there is no approved disease-modifying treatment

(7). The difficulty of conducting clinical trials for AD treatments is exacerbated by the use of conventional outcome measures that are insensitive to change early in disease and sensitive to environmentally-induced variation. By capturing alternative outcome measures in real-world settings, digital devices have the potential to mitigate these problems, thereby expediting trials, lowering costs, and enabling more effective clinical trials. Digital tools can also promote inclusiveness and social justice, increase the pool of participants, decrease sample size, and increase trial effectiveness by improving the generalizability and representation of vulnerable populations. Smartphones hold particular promise in the realm of digital tools since they are among the most penetrating technologies available, with over three billion users worldwide (8).

However, converting trial outcomes from in-person to
remote measures is also associated with many challenges.
Among the most critical aspects to be considered are
usability and the reliability and fidelity of technology-
related measures (9). Consumer-oriented devices and
apps must be scaled for use in clinical trial settings and
confounds introduced by remote assessment must be
addressed. User training and support will be critical to
reduce user errors. Technologies themselves should not
drive their use in clinical trials; rather the use case should
drive the technology.

In the AD space, digital tools have shown particular
promise in capturing subtle cognitive and functional
changes in preclinical AD. Yet there remain questions
regarding their ability to serve as outcome measures due
to questions around feasibility, reliability, and validity.

Implementing digital devices in AD clinical
studies

As the COVID-19 pandemic has necessitated moving
clinical trials from specialized centers to home-based
virtual assessments using both passive and active
measures, investigators are learning lessons that have
the potential to accelerate all clinical trials for dementia.
Indirect measures of behavior, function, and physiology
are being explored as cognitive and functional endpoints
for clinical trials by individual research groups as well
as technology companies. For example, Elektra Labs has
created the Atlas platform, which takes a data science
approach to clinical trials through the application of a
wide selection of connected sensors and physiological
and behavioral markers.

Many research groups that have developed and/
or implemented digital technologies in clinical studies
presented data and plans to the Task Force, providing
lessons learned as well as strategies for moving forward:
<figure><img src="image_3.png" /><figcaption>**Figure 1.** Pervasive Computing and Continuous Monitoring Demonstrate Effects of COVID-19 Pandemic on Loneliness and Physical Activity</figcaption></figure>

In two separate cohorts, digital data streams provided by the CART ORCATECH platform demonstrated changes in mood (through online self-reported questionnaires) and physical activity (through actigraphy) that coincided with the imposition of stay-at-home orders because of the pandemic.

## CART/ORCATECH Platform

The Collaborative Aging Research Using Technology (CART) Initiative funded by the US National Institutes of Health and the Department of Veterans Affairs, has developed a multi-functional digital assessment platform that is technology agnostic, use case flexible, sharable, and scalable (10). The platform, an extension of the Oregon Center for Aging & Technology (ORCATECH) assessment system at Oregon Health and Science University has been deployed to 301 older adults for up to three years in four US regions. It enables unobtrusive, long-term assessment across multiple domains (e.g., mobility, cognitive function, sleep) through the use of many different sensors and connected devices (e.g., electronic pillboxes, bed mats, actigraphs, online reporting on laptops, tablets or smartphones). The platform is currently deployed by multiple groups in the United States and Canada, with plans to extend the platform to France (in the community-wide INSPIRE study based at Toulouse University Hospital) and Australia. Testing in two cohorts -- a low-income housing cohort in Portland, Oregon, and an African-American Minority Aging Research Study (MARS) cohort in Chicago - gathered data spanning the time period of the pandemic demonstrating increased loneliness and decreased physical activity (Figure 1). In a proof-of-concept trial, the platform has also demonstrated feasibility for monitoring and predicting agitation among residents of memory care facilities (11), suggesting that it

may be possible to demonstrate the efficacy of treatments for agitation with sensors that monitor life-space activity.

## RADAR-AD

The public private partnership Remote Assessment of Disease and Relapse - AD (RADAR-AD), funded by the Innovative Medicines Initiative (IMI) has embraced an "internet of things" (IOT) approach similar to the CART/ORCATECH system to measure early decline in cognitive function using low friction digital devices across a range of challenges. A study is planned that will enroll 200 participants over age 50 including those with preclinical AD, MCI due to AD, mild-to-moderate AD, and age and gender matched controls. RADAR earlier launched a multi-site prospective cohort study to determine the feasibility, usability, and acceptability of remote measurement technology (RMT) for major depressive disorder (MDD) (12).

Remote digital measurements that may be used in RADAR-AD include adaptations of multiple instruments to be administered using a table or smartphone interface such as the Amsterdam-instrumental activities of daily living questionnaire (A-IADL-Q) (13) to assess orientation, planning skills, and memory; and the Patient-Reported Outcomes Measurement Information Systems (PROMIS) general health measures to assess quality of life, disabilities, pain, and fatigue (14).

The RADAR base app, using a smartphone and passive sensors, will assess mobility, social communication, time
at home, general activity, and sleep duration and quality. A residential movement detector will also assess gait and mobility at home and time spent in different areas of the home. The Mezurio smartphone app will capture high-frequency data related to cognition, including sleep, planning, memory, mood and anxiety, voice and speech, and typing and swiping (15).

## Harvard Aging Brain Study (HABS)

In its search for sensitive measures of subtle cognitive decline in preclinical AD, The Harvard Aging Brain Study (HABS) developed an iPad-based Computerized Cognitive Composite (C3) and subsequently a smartphone-based tool for remote assessment of memory. The C3 on the iPAD comprises 3 components: a Behavioral Pattern Separation task, a Face-Name Associative Memory Exam, and the Cogstate Brief Battery. Development of the C3 included its use in the A4 study, a secondary prevention trial in clinically normal older adults with abnormal levels of amyloid who were randomized to receive placebo or solanezumab. This initial study showed that when the drug was administered in screening period, the amyloid-positive group performed worse on C3 compared to the Preclinical Alzheimer Cognitive Composite (PACC) (16, 17). The C3 has also been shown to provide reliable data when participants complete the assessments at home on an iPad (18). The remote use of C3 allows for more frequent assessments, which provide new information about subtle cognitive changes (19).

HABS has also developed the Boston Remote Assessment for Neurocognitive Health (BRANCH), which combines two paired associative learning tasks, an associated memory test, and a continuous visual recognition task accessible on a smartphone. In a recent study, BRANCH was shown to be correlated with scores on the paper-based preclinical Alzheimer's cognitive composite (PACC5) (20).

HABS investigators have also been using BRANCH to assess learning curves using data from clinically normal older adults who completed 5 consecutive days of BRANCH. Early evidence suggests that a steeper learning curve is associated with better performance on the PACC, although the results were not statistically significant. Nonetheless, capturing learning curves using a smartphone over several days appears to be feasible and valid and may be useful to prescreen potential trial participants for biomarker status and identify those at greater risk for imminent cognitive decline and most likely to benefit from treatment. Cognitive learning curves may also serve as a paradigm for exploring psychopharmacokinetic profiles of medications to assess for efficacy over relatively short time periods.

## The Trial-Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (TRC-PAD)

The Trial-Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (TRC-PAD) was established to accelerate drug development for AD by ensuring timely recruitment of targeted individuals into optimally designed preclinical and prodromal trials. TRC-PAD gathers multiple types of data including digital data from wearables and sensors through its informatics platform (TRC-PAD IP). In concert with TRC-PAD, the Alzheimer's APT Webstudy registry was established along with an analytics platform, a referral management system, and a data management system (21).

The APT Webstudy has been working to optimize digital smartphone-based tools to assess cognition, such as the Cogstate Brief Battery. The study plans to implement this tool in the AHEAD 3-45 secondary prevention trials in early preclinical and preclinical AD and in the CT1812 trial in early AD (22). APT is also exploring alternative remote testing sensitive to amyloid elevation.

## WHO – Integrated Care for Older People (ICOPE) Monitor

In its World Report on Healthy Ageing, the World Health Organization (WHO) redefined healthy aging in terms of functional ability, which is a product of an individual's intrinsic capacity (IC) interacting with the environment (23). In order to implement integrated care for older people (ICOPE), an international partnership of researchers have developed a tool for assessing IC (24) as well as a mobile app available on smartphones that enable self-assessment by individuals to provide health care professionals with data on intrinsic capacity (25). Initial results from more than 5300 older individuals in the ICOPE Digital Cohort report high levels of IC impairments in multiple domains, including in vision, hearing, psychological health, and cognition. Recognizing that additional cognitive assessments are needed, ICOPE data will be combined with the Alzheimer's Prevention Trial (APT) Webstudy data beginning in 2021. The ICOPE integrative approach from WHO provides the opportunity to detect memory complaints or decline, taking into consideration declines in other ICs, such as vision, hearing, mood, nutrition.

## Brain Health Registry

With a goal of improving clinical trial recruitment, the Brain Health Registry (BHR) was established in 2014 as a website and online registry that collects digital data from potential clinical trial participants and study partners through self-report questionnaires and neuropsychological tests. Among the over 70,000 individuals enrolled in BHR, there have been over 106,000
referrals and 5,000 enrolled in other clinical studies. Through co-enrollment, BHR and clinical trial data can be linked.

BHR is also involved in methods development and validation of new online methods, including an electronic Clinical Dementia Rating (CDR) scale, a digital financial capacity instrument, and other digital assessment tools. In support of blood biomarkers studies, BHR has also collaborated with Quest Diagnostics to scale up blood collection using remote identification through the registry.

## Other Studies Incorporating Digital Assessment Tools

Many other clinical research programs are exploring using digital measures of cognition and function (e.g., web- or mobile- device based cognitive testing, automated speech and language assessment, or use of sensor-embedded home-based device responsives). For example, the Framingham Heart Study (FHS) is developing a smartphone platform with multiple applications including digital voice. Voice (spoken utterances and language) is measured through device agnostic technologies and FHS research shows that linguistic and acoustic measures can be used as biomarkers of cognitive function (26-28). However, while speech and language assessments are likely to be very sensitive, additional work is needed to determine the best way to capture speech samples.

The Deep and Frequent Phenotyping (DFP) study in the United Kingdom has also incorporated digital measures from wearables and smartphones to capture highly granular data on gait, memory, navigational ability, and other measures that may serve as proxies for cognition and function (29). The study aims to identify an optimal set of markers for patient stratification.

## Potential benefits and challenges associated with incorporating digital tools in trials

Digital devices offer the potential to expedite clinical trials, reduce the sample sizes or duration of studies, lower the cost of acquiring and analyzing data, enable the recruitment of more diverse and representative populations, reduce the need for specialized raters, reduce rater burden, and increase the clinical meaningfulness of outcome data collected to determine efficacy of an intervention. During a pandemic, digital tools also may provide the means for remote assessments, which could mitigate problems associated with closure of clinical trial sites and the safety concerns associated with in-person assessments and interventions.

Combining cognitive and functional endpoints in clinical trials is well established through the use of questionnaires in symptomatic stages of disease; and in preclinical disease, reports from both participants and

study partners regarding high-level functional activities appear to provide valuable information on disease trajectory. Pairing digital cognitive measures with digital functional assessments may offer increased sensitivity in preclinical disease. The HABS team has shown that functional inventories can be administered remotely through the use of REDCap software, saving time and reducing data errors without sacrificing data quality.

The technologies employed in various digital devices provide additional potential advantages:

* They allow data to be time stamped, which enables assessment of everyday function.

* They can improve participant compliance by providing study participants and partners with reminders to take medications and engage in study-related activities.

* Audio and video recordings can provide a level of biometric validation to ensure that study participants themselves (rather than study partners) are providing data.

* Passive sensing of activities such as driving and computer use have demonstrated unique personalized patterns that can be captured using relatively simple algorithms.

* Passive sensors reduce participant burden, thus potentially reducing drop-outs and producing outcomes that are easily understandable and relevant in a real-world context.

* Meta-data such as time taken to complete a questionnaire or remember to take medication on time may also reflect changes in episodic memory, a key domain affected in AD.

* Passive assessment of sleep may prove useful since disrupted sleep has been shown to be a mediator of amyloid deposition in many studies.

To achieve the promise of digital devices will require addressing many challenges including those related to reliability, validation, user acceptability, regulatory approval, privacy and security. While regulators have indicated a willingness to consider digital data, much work remains to be completed before digital measures are accepted as primary or secondary outcomes. Indeed, the FDA issued guidance on the conduct of trials during a pandemic which includes increased flexibility around trial procedures intended to maintain participant safety, but less flexibility around efficacy measures. Task Force members also questioned whether regulators would accept remotely acquired data where there is no assurance that study participants and not study partners completed questionnaires or cognitive outcome assessments.

While digital registries may enable outreach to otherwise under-represented populations, engagement and retention of trial participants through digital means alone may be insufficient. Indeed, studies have reported high compliance rates that they attribute to personalized rather than anonymous digital engagement of study
participants (30).

Transitioning cognitive assessments to smartphones may enable more frequent and sensitive measurement among large numbers of participants in a short period of time. However, smartphones may introduce additional challenges with regard to data fidelity and security. Other technological challenges related to digital data include the difficulty of analyzing continuous data and deconvoluting diverse data captured by devices. Addressing these challenges will be advanced by wider collaboration with the computer science and data science community.

Digital readouts are diverse and non-standardized, which results in impediments to data aggregation and sharing of data, both of which are essential to advance the field. Collaboration among technology developers is needed to ensure that raw data from which readouts on different devices are derived will be made available to the research community. Privacy concerns represent an additional roadblock to data sharing. Federated data management platforms have been developed that provide researchers with access to multiple types of data from multiple sources (31). The Alzheimer's Disease Data Initiative has also established the AD Workbench (ADWB) platform to promote data, information, and tool sharing across the AD research community (32), although no digital biomarker data are yet incorporated in this relatively new effort.

## Moving Forward

Despite the challenges of conducting clinical studies during the pandemic, the AD clinical research community remains committed to advancing current studies and launching new studies. Indeed, Task Force participants suggested that the COVID-19 experience may fuel preparations for better clinical trials that mitigate both the risks associated with the pandemic and more common complications of clinical trials for example by broadening the reach of recruitment efforts.

Among the possibilities discussed by the Task Force was the potential to design completely digital or hybrid trials combining virtual/telemedicine and physical visits. For example, telemedicine consultations in the pre-screening phase of a trial could help verify inclusion and exclusion criteria, provide information to potential trial participants, and obtain electronic consent. Virtual visits could also be used for trial components that do not require technically invasive procedures. The INSPIRE study team at Toulouse University Hospital tested this strategy following the first COVID lockdown in France and found a high rate of acceptance among participants (33).

Digital devices may provide new analytical methods as well, for example, by enabling assessment of intraindividual change in a high frequency way. Digital tools implemented during the pandemic may also

provide increased understanding to the effects of daily stress, anxiety, and poor sleep on cognitive outcomes. They may also enable continued assessment of cognitive function in participants post-infection with COVID-19.

To ensure that clinical studies continue through the pandemic and its aftermath, the Task Force recommended that regulators and institutional review boards provide guidance yet maintain flexibility with regard to changes in applications devices and statistical plans and allow for virtual and home-based visits and remote monitoring. Developers must consider alternate or additional trial sites, and funders should expect unanticipated modifications to protocols and funding needs.

The Task Force concluded its session with a discussion of the field's readiness to conduct remote clinical trials. Task Force members urged caution in employing remote assessments for trials of experimental medications; the digital measures at this time may be most productively embedded in parallel with conventional measures in early-stage Phase 1 and 2 trials, demonstrating their fidelity or even superiority to current commonly used clinical outcome measures. Enthusiasm was expressed for using digital technologies in remote studies of non-invasive interventions such as studies of vitamins, exercise, and mind-body or multidomain approaches. Trials of repurposed drugs for which safety data exists may also be feasible as entirely remote trials. For example, because of the COVID-19 pandemic, the Alzheimer's Disease Cooperative Study (ADCS) is attempting to conduct the PEACE-AD (prazosin for disruptive agitation in Alzheimer's disease) trial (34) as a remote-only trial.

**Acknowledgements:** The authors thank Lisa J. Bain for assistance in the preparation of this manuscript.

**Conflicts of interest:** The Task Force was partially funded by registration fees from industrial participants. These corporations placed no restrictions on this work. Dr. Kaye reports grants from Merck, Eisai, Genentech, and Abbvie; and serves on a Data Safety Monitoring Committee at Eli Lilly. Dr. Aisen reports grants from Janssen, Eli Lilly, Eisai, NIA, the Alzheimer's Association, and FNIH; and consulting fees from Biogen, Roche, Merck, Abbvie, Lundbeck, Proclara, and Immunobrain Checkpoint. Dr. Amariglio declares there are no conflicts. Dr. Au is on the scientific advisory board of Signant Health and a consultant to Biogen. Dr. Ballard reports grants from Arcadia pharmaceutical company and Lundbeck; personal fees from Arcadia, Lundbeck, Roche, Otsuka, Novartis, Eli Lilly, Suven, Sunovion, ADDEX, and Exciva; personal fees and other from Synexus, Novo Nordisk; and consulting fees from Biogen. Dr. Carillo declares there are no conflicts. Dr. Fillit declares there are no conflicts. Dr. Iwatsubo declares there are no conflicts. Dr. Jimenez-Maggiora declares there are no conflicts. Dr. Lovestone is an employee of Janssen Medical Ltd and a co-founder of Akrivia Health Ltd. Dr. Natanegara is an employee of Eli Lilly and Company. Dr. Papp declares there are no conflicts. Dr. Soto declares payment as consultant or advisor from Avanir, Acadia. Dr. Weiner reports grants from Siemens, Biogen, and Johnson & Johnson, NIH, California Department of Health, University of Michigan, Hillblom Foundation, Alzheimer's Association, State of California, Kevin and Connie Shanahan, GE, VUMc, American Catholic University, The Stroke Foundation, and the Veteran's Administration; has served on advisory boards for Eli Lilly, Cerecin/Accera, Roche, Alzheon Inc., Merck Sharp & Dohme Corp, Nestle/Nestec; and has consulted with or acted as a speaker to Cerecin/Accera Inc., BioClinica, Nestle/Nestec, Genentech, FUJIFILM-Toyama Chemical, and T3D Therapeutics; and holds stock options with Alzheon Inc, Alzeca, and Anven. Dr. Vellas reports grants from Lilly, Merck, Roche, Lundbeck, Biogen, grants from Alzheimer's Association, European Commission, personal fees from Lilly, Merck, Roche, Biogen, outside the submitted work.

**Open Access:** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution and
reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

## References

1. Morris MC, Tangney CC, Wang Y, et al. MIND diet slows cognitive decline in 1. van Dorn A. COVID-19 and readjusting clinical trials. The Lancet. 2020 Aug 22;396(10250):523-4.

2. Fleming TR, Labriola D, Wittes J. Conducting Clinical Research During the COVID-19 Pandemic: Protecting Scientific Integrity. JAMA. 2020 Jul 7;324(1):33-4.

3. Sathian B, Asim M, Banerjee I, Pizarro AB, Roy B, van Teijlingen ER, et al. Impact of COVID-19 on clinical trials and clinical research: A systematic review. Nepal J Epidemiol. 2020 Sep;10(3):878-87.

4. Brown EE, Kumar S, Rajji TK, Pollock BG, Mulsant BH. Anticipating and Mitigating the Impact of the COVID-19 Pandemic on Alzheimer's Disease and Related Dementias. Am J Geriatr Psychiatry. 2020 Jul;28(7):712-21.

5. Food and Drug Administration. Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency Guidance for Industry, Investigators, and Institutional Review Boards. U.S. Department of Health and Human Services.; 2020.

6. Gold M, Amatniek J, Carrillo MC, Cedarbaum JM, Hendrix JA, Miller BB, et al. Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials. Alzheimers Dement (N Y). 2018;4:234-42.

7. World Health Organization. Dementia [Internet]. 2020 [cited 2021 Jan 6].
Available from: https://www.who.int/news-room/fact-sheets/detail/dementia

8. Statista. Number of smartphone users worldwide from 2016 to 2021 [Internet]. Statista. 2020 [cited 2021 Jan 26]. Available from: https://www.statista.com/statistics/330695/number-of-smartphone-users-worldwide/

9. Lindauer A, Seelye A, Lyons B, Dodge HH, Mattek N, Mincks K, et al. Dementia Care Comes Home: Patient and Caregiver Assessment via Telemedicine. Gerontologist. 2017 Oct 1;57(5):e85-93.

10. Beattie Z, Miller LM, Almirola C, Au-Yeung W-TM, Bernard H, Cosgrove KE, et al. The Collaborative Aging Research Using Technology Initiative: An Open, Sharable, Technology-Agnostic Platform for the Research Community. Digit Biomark. 2020;4(Suppl 1):100-18.

11. Au-Yeung W-TM, Miller L, Beattie Z, Dodge HH, Reynolds C, Vahia I, et al. Sensing a problem: Proof of concept for characterizing and predicting agitation. Alzheimers Dement (N Y). 2020;6(1):e12079.

12. Matcham F, Barattieri di San Pietro C, Bulgari V, de Girolamo G, Dobson R, Eriksson H, et al. Remote assessment of disease and relapse in major depressive disorder (RADAR-MDD): a multi-centre prospective cohort study protocol. BMC Psychiatry. 2019 Feb 18;19(1):72.

13. Stringer G, Leroi I, Sikkes SAM, Montaldi D, Brown LJE. Enhancing 'meaningfulness' of functional assessments: UK adaptation of the Amsterdam IADL questionnaire. International Psychogeriatrics. undefined/ed;1-12.

14. Tatsuoka C, DeMarco L, Smyth KA, Wilkes S, Howland M, Lerner AJ, et al. Evaluating PROMIS Physical Function Measures in Older Adults at Risk for Alzheimer's Disease. Gerontol Geriatr Med [Internet]. 2016 Sep 5 [cited 2021 Jan 8];2. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590694/

15. Lancaster C, Koychev I, Blane J, Chinner A, Wolters L, Hinds C. Evaluating the Feasibility of Frequent Cognitive Assessment Using the Mezurio Smartphone App: Observational and Interview Study in Adults With Elevated Dementia Risk. JMIR Mhealth Uhealth [Internet]. 2020 Apr 2 [cited 2021 Jan 8];8(4).
Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7163418/

16. Papp KV, Rentz DM, Maruff P, Sun C-K, Raman R, Donohue MC, et al. The Computerized Cognitive Composite (C3) in A4, an Alzheimer's Disease Secondary Prevention Trial. J Prev Alzheimers Dis. 2021;8(1):59-67.

17. Papp KV, Rentz DM, Orlovsky I, Sperling RA, Mormino EC. Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5. Alzheimers Dement (N Y). 2017 Nov;3(4):668-77.

18. Rentz D, Dekhtyar D, Sherman J, Burnham S, Blacker D, Aghjayan S, et al. The Feasibility of At-Home iPad Cognitive Testing For Use in Clinical Trials. 2015 [cited 2021 Jan 8]; Available from: http://www.jpreventionalalzheimer.com/all-issues.html?article=148

19. Samaroo A, Amariglio RE, Burnham S, Sparks P, Properzi M, Schultz AP, et al. Diminished Learning Over Repeated Exposures (LORE) in preclinical Alzheimer's disease. Alzheimers Dement (Amst). 2020;12(1):e12132.

20. Papp KV, Samaroo AH, Chou H-CL, Buckley RF, Rentz D, Sperling RA, et al. Repeated memory-based assessments: Implications for clinical trials and practice. Alzheimer's & Dementia. 2020;16(S6):e038143.

21. Jimenez-Maggiora GA, Bruschi S, Raman R, Langford O, Donohue M, Rafii MS, et al. TRC-PAD: Accelerating Recruitment of AD Clinical Trials through Innovative Information Technology. J Prev Alzheimers Dis. 2020;7(4):226-33.

22. Grundman M, Morgan R, Lickliter JD, Schneider LS, DeKosky S, Izzo NJ, et al. A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease. Alzheimers Dement (N Y). 2019 Jan 23;5:20-6.

23. Beard JR, Officer A, de Carvalho IA, Sadana R, Pot AM, Michel J-P, et al. The World report on ageing and health: a policy framework for healthy ageing. Lancet. 2016 May 21;387(10033):2145-54.

24. Takeda C, Guyonnet S, Sumi Y, Vellas B, Araujo de Carvalho I. Integrated Care for Older People and the Implementation in the INSPIRE Care Cohort. J Prev Alzheimers Dis. 2020;7(2):70-4.

25. Sanchez-Rodriguez D, Annweiler C, Gillain S, Vellas B. Implementation of the Integrated Care of Older People (ICOVE) App in Primary Care: New Technologies in Geriatric Care During Quarantine of COVID-19 and Beyond. J Frailty Aging. 2020 May 6;1-2.

26. Thomas JA, Burkhardt HA, Chaudhry S, Ngo AD, Sharma S, Zhang L, et al. Assessing the Utility of Language and Voice Biomarkers to Predict Cognitive Impairment in the Framingham Heart Study Cognitive Aging Cohort Data. J Alzheimers Dis. 2020;76(3):905-22.

27. Thomas NWD, Beattie Z, Marcoe J, Wright K, Sharma N, Mattek N, et al. An Ecologically Valid, Longitudinal, and Unbiased Assessment of Treatment Efficacy in Alzheimer Disease (the EVALUATE-AD Trial): Proof-of-Concept Study. JMIR Res Protoc. 2020 May 27;9(5):e17603.

28. Lin H, Karjadi C, Ang TFA, Prajakta J, McManus C, Alhanai TW, et al. Identification of digital voice biomarkers for cognitive health. Exploration of Medicine. 2020 Dec 31;1(6):406-17.

29. Koychev I, Lawson J, Chessell T, Mackay C, Gunn R, Sahakian B, et al. Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer's disease. BMJ Open. 2019 Mar 23;9(3):e024498.

30. Sano M, Egelko S, Zhu CW, Li C, Donohue MC, Ferris S, et al. Participant satisfaction with dementia prevention research: Results from Home-Based Assessment trial. Alzheimers Dement. 2018;14(11):1397-405.

31. Toga AW, Bhatt P, Ashish N. Global data sharing in Alzheimer's disease research. Alzheimer Dis Assoc Disord. 2016;30(2):160-8.

32. Alzheimer's Disease Data Initiative. AD Workbench [Internet]. ADDI. [cited 2021 Jan 11]. Available from: https://www.alzheimersdata.org/ad-workbench

33. Takeda C, Guyonnet S, Ousset PJ, Soto M, Vellas B. Toulouse Alzheimer's Clinical Research Center Recovery after the COVID-19 Crisis: Telemedicine an Innovative Solution for Clinical Research during the Coronavirus Pandemic. J Prev Alzheimers Dis. 2020;7(4):301-4.

34. Alzheimer Disease Cooperative Study. PEACE-AD [Internet]. ADCS PEACE-AD. [cited 2021 Jan 11]. Available from: https://www.adcs.org/peace-ad/

How to cite this article: J. Kaye, P. Aisen, R. Amariglio et al. Using Digital Tools to Advance Alzheimer's Drug Trials During a Pandemic: The EU/US CTAD Task Force. J Prev Alz Dis 2021;4(8):513-519; http://dx.doi.org/10.14283/jpad.2021.36